



## OPHTHAMOLOGICAL DISEASES

*Some important facts from Central and Eastern Europe,  
Central Asia and Central America.*

Ophthalmological diseases are varied in form and in gravity, but all of them have in common a huge social impact on the persons suffering from them. According to the World Health Organization, there are estimated 180 million people worldwide who are visually impaired, and between 40 and 45 million of them are blind. The major causes of avoidable vision loss are cataract, trachoma and glaucoma. All three of them account for more than 70% of the world's blindness.

Let's take a closer look at this problem called glaucoma: this disease is responsible for about 5.5 million new cases of blindness every year. The estimates of the number of persons worldwide who have glaucoma range from about 67 million (according to The Glaucoma Foundation) to about 105 "suspect" cases of glaucoma (WHO figures).

Having in mind all of the abovementioned, intensive efforts in clinical investigation are being made worldwide to fight against these diseases. We at S&P Pharmatest do also care about ophthalmological diseases and have made it one of our main focus of attention. Though our successful organization of the most different clinical trials phases II and III (also in the ophthalmological area), we have built a competitive and efficient network of trial centres in Central and Eastern Europe, as well as in Central Asia and Central America.

We proudly would like to indicate you that not only the quality of the facts is absolutely impeccable thanks to intensive professional training and care measures, but also, and mostly, that the recruitment speed is correct and that our sponsors are highly satisfied. Our regional project and monitoring teams, where many ophthalmologists work, ensure a rapid development and a high quality of the trials and projects by us represented in various countries in Central and Eastern Europe, Central Asia and Central America. The centres in our ophthalmological network are always receiving new patients suffering from the most varied eye problems, thus ensuring a large pool of subjects for clinical studies. They are also audit certified, and are prepared to take on your study. We are happy to be at your disposal for further information or to answer your questions. All the ophthalmological centres working with us do have the necessary laboratory equipment and diagnosis possibilities for clinical trials on this indication.

Thus we are taking the liberty of sending you a brief questionnaire on the next page which we ask you to fax back if interested.

Yours truly,

Dr. Alexander Siebel  
Medical & Managing Director